<DOC>
	<DOCNO>NCT01941004</DOCNO>
	<brief_summary>To evaluate safety efficacy fingolimod 0.5mg vs. placebo MS patient China</brief_summary>
	<brief_title>Safety Efficacy Fingolimod MS Patients China</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients must relapse remit multiple sclerosis Patients : History chronic immune disease Certain cancer Uncontrolled diabetes Certain eye disorder Negative varicella zoster virus IgG antibodies Certain hepatic condition Low white blood cell count On certain immunosuppressive medication heart medication Certain heart condition certain lung condition Inability undergo MRI scan Diagnosis Neuromyelitis optica . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>multiple sclerosis ( MS )</keyword>
	<keyword>relapse remit multiple sclerosis ( RRMS )</keyword>
	<keyword>fingolimod</keyword>
</DOC>